三个皮匠报告—— 严选型全行业研究报告分享下载平台,您的专属行业智库!
欢迎来到三个皮匠报告!
登录
帮助中心
首页
最新
研搜
BETA
合集
英文
会议
数据
财报库
政策库
自研报告
入驻
您的当前位置:
首页
>
行业数据
>
图12.乌帕替尼与度普利尤单抗头对头研究EASI-75与EASI-90应答率对比
图12.乌帕替尼与度普利尤单抗头对头研究EASI-75与EASI-90应答率对比
行业数据
下载Excel
下载图片
原图定位
图片属性
图片格式:PNG
图片大小:197KB
图片尺寸:1888*849
同报告图片
/
4
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
所属报告:
泽璟制药-公司研究报告-创新药平台型新龙头崛起核心管线进入兑现期-230731(37页).pdf
打包全文图表
相关数据
度普利尤单抗(达必妥)全球销售额(2017-2025年)
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
收藏
行业数据
2026-05-28
原图定位
查看详情
度普利尤单抗2024年销售额超140亿美元,持续快速放量中
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
收藏
行业数据
2025-12-26
原图定位
查看详情
截至2025年9月底,度普利尤单抗、司普奇拜单抗分别获批8项、3项适应症,且适应症持续拓展
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
收藏
行业数据
2025-12-26
原图定位
查看详情
度普利尤单抗全球范围销售收入
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
收藏
行业数据
2025-11-21
原图定位
查看详情
全球首个FGFR4抑制剂联合IO在HCC的临床设计:依帕戈替尼联合阿替利珠单抗的临床二期试验方案
PHxiZWdpbl9vZl9ib3h8PnwgUGFydCB8IERvc2UgUmVnaW1lbiAgICAgICB8IFNhbXBsZSBTaXplIChOKSB8CnwtLS0tLS18LS0tLS0tLS0tLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tLS0tLS18CnwgQSAgICB8IDE4MG1nIFFEICAgICAgICAgICB8IDYgICAgICAgICAgICAgICB8CnwgQSAgICB8IDMyMG1nIFFEICAgICAgICAgICB8IDYgICAgICAgICAgICAgICB8CnwgQSAgICB8IDE2MG1nIEJJRCAgICAgICAgICB8IDggICAgICAgICAgICAgICB8CnwgQSAgICB8IDIyMG1nIEJJRCAgICAgICAgICB8IDMzICAgICAgICAgICAgICB8CgrotYTmlpnmnaXmupDvvJrlhazlj7hQUFQ8fGVuZF9vZl9ib3h8Pg==
收藏
行业数据
2025-10-10
原图定位
查看详情
全球几款早于和誉依帕戈替尼进入临床阶段的FGFR4抑制剂,大部分都已经停止开发
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
收藏
行业数据
2025-10-10
原图定位
查看详情
全球约30%的肝细胞癌患者存在异常的FGF19-FGFR4通路改变,依帕戈替尼(ABSK011)的独特设计MoA
fCDlnLDljLogICB8IOavj+W5tOaWsOWinueXheS+i+aVsCB8CnwtLS0tLS0tLXwtLS0tLS0tLS0tLS0tLS0tfAp8IOWFqOeQgyAgIHwg57qmMzDkuIcgICAgICAgICB8Cnwg5Lit5Zu9ICAgfCDnuqYxNeS4hyAgICAgICAgIHwKCui1hOaWmeadpea6kO+8muWFrOWPuFBQVO+8jOS+neW4leaIiOabv+WwvOmAmui/h+mdtuWQkUZHRjE5IC0gRkdGUjQg6YCa6Lev5rK755aX6IKd55mM
收藏
行业数据
2025-10-10
原图定位
查看详情
针对肝癌目前1L/2L治疗方案的ORR较低,mPFS较短,依帕戈替尼(ABSK011)有望改变这一状况
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
收藏
行业数据
2025-10-10
原图定位
查看详情
吡咯替尼或在国内乳腺癌新辅助治疗领域扮演帕妥珠单抗角色
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
收藏
行业数据
2025-09-28
原图定位
查看详情
度普利尤单抗销售额2024年超140亿美元,仍呈现快速增长态势
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
收藏
行业数据
2025-09-17
原图定位
查看详情
度普利尤单抗销售额2024年超140亿美元,仍呈现快速增长态势
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
收藏
行业数据
2025-09-17
原图定位
查看详情
611治疗特异性皮炎的EASI75及NRS优于度普利尤单抗(II期数据)
fCBDb21wYW55IHwgSW5kaWNhdGlvbiB8IENvZGUgfAp8IC0tLSB8IC0tLSB8IC0tLSB8CnwgQSB8IEFEIGFwcHJvdmVkIHwgIHwKfCBCIHwgQXN0aG1hIE5EQSByZXZpZXdpbmcgfCAgfAp8IDNTQmlvIHwgQXN0aG1hIFBoYXNlIElJIGNvbXBsZXRlZCB8ICB8CnwgIHwgQUQgUGhhc2UgSUlJIHwgIHwKfCAgfCBDUlN3TlAgUGhhc2UgSUlJIHwgIHwKfCAgfCBDT1BEIFBoYXNlIElJIHwgIHwKfCAgfCBTU0dKLTYxMSB8ICB8CgrotYTmlpnmnaXmupDvvJrkuInnlJ/liLboja/lhazlj7jlrpjnvZHvvIzlm73nm5vor4HliLjnoJTnqbbmiYA=
收藏
行业数据
2025-03-24
原图定位
查看详情
2017-2023年度普利尤单抗全球销售额(亿美元)
fCDlubTku70gfCDplIDllK7pop3vvIjkur/nvo7lhYPvvIkgfAp8LS0tLS0tfC0tLS0tLS0tLS0tLS0tLS18CnwgMjAxNyB8IDIuNDcgICAgICAgICAgIHwKfCAyMDE4IHwgOS4zMSAgICAgICAgICAgfAp8IDIwMTkgfCAyMy4zICAgICAgICAgICB8CnwgMjAyMCB8IDM5LjA3ICAgICAgICAgIHwKfCAyMDIxIHwgNjQuMSAgICAgICAgICAgfAp8IDIwMjIgfCA5NC4yOCAgICAgICAgICB8CnwgMjAyMyB8IDExNC42MyAgICAgICAgIHwKCui1hOaWmeadpea6kO+8mui1m+ivuuiPsuWumOe9keOAgeS4nOWMl+ivgeWIuA==
收藏
行业数据
2025-02-24
原图定位
查看详情
图17.度普利尤单抗的不良反应发生率整体与安慰剂类似
5aW955qE77yM5Lul5LiL5piv5Zu+54mH5Lit55qE5pWw5o2u55Sf5oiQ55qE6KGo5qC877yM5Lul5Y+K5a+55bqU55qE6LWE5paZ5p2l5rqQ77yaCgp8IOS6i+S7tuexu+WeiyB8IER1cGlsdW1hYiDnu4QgKE49NDY5KSB8IOWuieaFsOWJgue7hCAoTj00NzApIHwKfCAtLS0gfCAtLS0gfCAtLS0gfAp8IOS7u+S9leS4jeiJr+S6i+S7tiB8IDc3LjQlIHwgNzYuMCUgfAp8IOS7u+S9leS4pemHjeS4jeiJr+S6i+S7tiB8IDEzLjYlIHwgMTUuNSUgfAp8IOm8u+WSveeCjiB8IDkuNCUgfCA5LjYlIHwKfCDkuIrlkbzlkLjpgZPmhJ/mn5MgfCA3LjklIHwgOS44JSB8Cnwg5aS055ebIHwgOC4xJSB8IDYuOCUgfAp8IENPUEQgfCA1LjglIHwgNi4wJSB8CgrotYTmlpnmnaXmupDvvJpEdXBpbHVtYWIgZm9yIENPUEQgd2l0aCBUeXBlIDIgSW5mbGFtbWF0aW9uIEluZGljYXRlZCBieSBFb3Npbm9waGlsIENvdW50c+OAgei0oumAmuivgeWIuOeglOeptuaJgA==
收藏
行业数据
2025-02-17
原图定位
查看详情
CM310临床疗效整体优于度普利尤单抗(非头对头)
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
收藏
行业数据
2024-12-27
原图定位
查看详情
最新数据
全球全年龄段奶粉市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球酸奶及发酵乳制品市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球药用级益生菌市场规模(百万美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球益生菌膳食补充剂市场规模及增速
收藏
行业数据
2026-07-30
原图定位
查看详情
全球拥有AKK专利菌株的核心企业
收藏
行业数据
2026-07-30
原图定位
查看详情
(2)乌帕替尼 Heads Up 研究:主要终点为 16周的 EASI-75应答率,结果显示第 12周 EASI-75应答率方面乌帕替尼显著优于度普利尤单抗,分别为 71%、61%。
行业数据
原图定位
当前图表所属:
泽璟制药-公司研究报告-创新药平台型新龙头崛起核心管线进入兑现期-230731(37页).pdf
克替尼骨自免领域临床开发进展
杰克替尼骨髓纤维化市场销售额测算
中危-2或高危骨髓纤维化治疗数据对比
骨髓纤维化在研药物
下载图片或Excel,需升级至尊VIP会员或「预见者」VIP
立即去升级
客服
商务合作
小程序
服务号
回到顶部
折叠
微信扫码登录
微信扫码登录
双重福利,扫码领取!
关注公众号『三个皮匠报告』,免费领取报告
1.100+最新优质行业报告
2.每周免费精选报告分享
手机快捷登录
账号登录
记住密码
忘记密码?
验证即登录,未注册将自动创建账号
获取验证码
收不到验证码注意事项
登录代表您已阅读并同意
《三个皮匠服务条款》